A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer

被引:0
作者
Takashi Kobayashi
Tomonobu Koizumi
Toshihide Agatsuma
Masanori Yasuo
Kenji Tsushima
Keishi Kubo
Seiichiro Eda
Hiroshi Kuraishi
Shigeru Koyama
Tsutomu Hachiya
Nariaki Ohura
机构
[1] Shinshu University Hospital,Comprehensive Cancer Center, Division of Clinical Oncology, Shinshu University School of Medicine
[2] Shinshu University School of Medicine,First Department of Internal Medicine
[3] Matsumoto Kyoritsu Hospital,Respiratory Division
[4] Nagano Red Cross Hospital,Respiratory Division
[5] Suwa Red Cross Hospital,Respiratory Division
[6] Saku Central Hospital,Respiratory Division
来源
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词
Chemo-refractory; Salvage therapy; EGFR-sensitive mutation; Chemotherapy; NSCLC;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1241 / 1246
页数:5
相关论文
共 323 条
[1]  
Matsuda T(2011)Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project Jpn J Clin Oncol 41 139-147
[2]  
Marugame T(2010)Cancer statistics, 2010 CA Cancer J Clin 60 277-300
[3]  
Kamo K(2009)American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small cell lung cancer J Clin Oncol 27 6251-6266
[4]  
Katanoda K(2002)Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 92-98
[5]  
Ajiki W(2005)Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123-132
[6]  
Sobue T(2005)Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen Clin Cancer Res 11 6414-6421
[7]  
Jemal A(2010)Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2380-2388
[8]  
Siegel R(2009)Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947-957
[9]  
Xu J(2006)Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations J Clin Oncol 24 3340-3346
[10]  
Ward E(2007)Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer Cancer Sci 98 1817-1824